AstraZeneca Newsroom

AstraZeneca China Operating Normally Amid Investigations

China DailyOct 31 01:28 ET

European Equities Traded in the US as American Depositary Receipts Down Sharply in Wednesday Trading

MT NewswiresOct 30 11:08 ET

AstraZeneca Reports Ongoing Investigation Against AstraZeneca China President

MT NewswiresOct 30 09:34 ET

AstraZeneca Senior Executive Is Under Investigation by Chinese Authorities

WSJOct 30 09:17 ET

Daiichi Sankyo And AstraZeneca Launch Three Phase 3 Trials For Datopotamab Deruxtecan-Based Combinations In Advanced Nonsquamous NSCLC; TROPION-Lung10, Lung14, And Lung15 Studies Target High PD-L1 Expression And EGFR Mutations With First Patients Dosed

BenzingaOct 30 08:03 ET

AION Labs Launches New AI Startup to Accelerate Identification of Active Small Molecules for Drug Discovery

PR NewswireOct 29 08:30 ET

Astrazeneca (AZN.US) has been approved for clinical trials in china for a new class 1 anti-cancer drug.

B-cell malignancies are a type of malignant disease originating from B lymphocytes.

Zhitong FinanceOct 28 22:11 ET

Express News | AstraZeneca Shares Are Trading Higher. The European Union Approved the Company's Fasenra as an Add-on Treatment as an Add-on Treatment for Adult Patients With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis

BenzingaOct 28 13:26 ET

Express News | Monopar Therapeutics Shares Down 17.3% Premarket; AstraZeneca Reports 9.9% Stake in Co

ReutersOct 28 06:51 ET

Express News | AstraZeneca Reports 9.9% Passive Stake in Monopar Therapeutics as of Oct 23 - SEC Filing

ReutersOct 28 06:09 ET

AstraZeneca's EGPA Add-on Treatment Receives EU Approval

MT NewswiresOct 28 03:31 ET

Fasenra Approved in the EU for Eosinophilic Granulomatosis With Polyangiitis

AstraZeneca Oct 28 00:00 ET

J.P. Morgan Remains a Buy on AstraZeneca (AZN)

TipRanksOct 25 20:05 ET · Ratings

Astrazeneca (AZN) Declines More Than Market: Some Information for Investors

Yahoo FinanceOct 25 18:15 ET

AstraZeneca Hits 4-week Low

Trading EconomicsOct 25 09:56 ET

Sanofi Posts Q3 Revenue Beat as Dupixent Sales Jump

Seeking AlphaOct 25 07:45 ET

Monopar Stock Skyrockets After Agreement With AstraZeneca's Unit On Wilson's Disease Drug: Retail On Cloud Nine

BarchartOct 24 13:10 ET

Monopar Therapeutics Shares Are Trading Higher After the Company Entered Into an Agreement With Alexion, AstraZeneca Rare Disease, for an Exclusive Worldwide License to ALXN-1840 for Wilson Disease.

BenzingaOct 24 09:31 ET

Monopar Shares Rise on AstraZeneca Licensing Deal

Dow JonesOct 24 09:16 ET

Katie Couric Introduces Lost Women of Science's Podcast Finding Dora Richardson, Which Uncovers the Story of the Forgotten Woman Who Developed Tamoxifen, A Groundbreaking Breast Cancer Drug

PR NewswireOct 24 08:55 ET